BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.
Frequently asked questions
What sector does Bergenbio ASA (BGBIO) operate in?
Bergenbio ASA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Bergenbio ASA (BGBIO) current stock price?
As of the latest data, Bergenbio ASA stock price is NOK 0.49, with a previous close of NOK 0.49.
What is Bergenbio ASA (BGBIO) current market capitalization?
Bergenbio ASA market cap is approximately 76.91 million.
What is Bergenbio ASA (BGBIO) Earnings Per Share (EPS)?
The trailing EPS is -NOK 2.61, and the forward EPS is -NOK 6.27.
Does Bergenbio ASA (BGBIO) pay dividends?
No. Bergenbio ASA does not pay a dividend.
What is Bergenbio ASA (BGBIO) beta (volatility) score?
Bergenbio ASA has a beta of 1.194, meaning its volatility is roughly in line with the market.